Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Reference trademark issue [Regulatives / Guidelines]

posted by rajasekharkakarla – India, 2018-07-24 11:05 (2249 d 03:11 ago) – Posting: # 19087
Views: 2,820

Dear All,

I prepared protocol for Mesalamine delayed-release tablets 1.2 gm for USFDA submission, i written reference name as Lialda™ (mesalamine) delayed release tablets 1.2 gm with trademark TM and the protocol was approved by EC. But as per COA it is mentioned as Lialda^®, there is change in trademark. kindly suggest whether i need to go with ammendment/not.

Regards'
Kakarla

Complete thread:

Reference trademark issuerajasekharkakarla 2018-07-24 09:05 [Regulatives / Guidelines]
- Note to File Helmut 2018-07-24 16:57
  - Note to File rajasekharkakarla 2018-07-30 13:37

Admin contact
23,228 posts in 4,879 threads, 1,652 registered users;
39 visitors (0 registered, 39 guests [including 10 identified bots]).
Forum time: 14:16 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge. Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz